🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06881004
Recruiting Observational

Biliary Dilatation National Special Disease Cohort in China

NCT06881004 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Observational
Started
2025-03-19
Last updated
2026-06-23

Condition(s) studied

Choledochal Cyst

Study summary

This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for bile duct dilatation. Based on this cohort, the study seeks to clarify the epidemiological characteristics, pathological features, standard classification, disease progression, cancer risk, and optimal timing for surgical intervention in patients with bile duct dilatation. Additionally, it will compare the perioperative risks, long-term outcomes, and quality of life among different types of patients (including Todani types I, IVa, and V) following surgical treatment, to establish standardized surgical treatment strategies for each type.

Eligibility

Sex
ALL
Min age
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients who have been definitive diagnosed with biliary dilation. 2. Patients aged between 0 and 80 years old, regardless of gender. 3. In line with the principle of informed consent: For the retrospective cohort of biliary dilation, exemption from signing the informed consent form is applied for, while for the prospective cohort, signing the informed consent form is required. Exclusion Criteria: * None

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tsinghua Chang Gung Hospital Beijing Beijing Municipality Recruiting

More Beijing Tsinghua Chang Gung Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06881004 on ClinicalTrials.gov ↗ ← All trials in China